

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.elsevier.com/locate/radcr](http://www.elsevier.com/locate/radcr)

## Case Report

# Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis

Martin Krupa, MD<sup>a,\*</sup>, Rina Nguyen, BS<sup>a</sup>, Jonathan Revels, DO<sup>b</sup>, Lester S. Johnson, MD, PhD, FACR<sup>a</sup>

<sup>a</sup> Department of Radiology, Eastern Virginia Medical School, 600 Gresham Drive, Norfolk, VA 23507, USA

<sup>b</sup> Department of Radiology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA

## ARTICLE INFO

## Article history:

Received 28 May 2018

Accepted 21 June 2018

## Keywords:

Cardiac amyloidosis

Transthyretin

Tc-99m pyrophosphate

## ABSTRACT

Cardiac amyloidosis is an under-appreciated cause of heart failure. Establishing a diagnosis is important because traditional heart failure treatment regimens can worsen left ventricular failure in this disease. Endomyocardial biopsy is the gold standard for diagnosis; however, scintigraphy with radiolabeled phosphate derivatives and cardiac magnetic resonance imaging have been shown to have high sensitivity and specificity in diagnosing cardiac amyloidosis. Furthermore, cardiac scintigraphy can reliably differentiate amyloid subtypes. We present a case of transthyretin-related cardiac amyloidosis with a negative endomyocardial biopsy but positive 99m-technetium pyrophosphate single photon emission computed tomography scan and cardiac magnetic resonance imaging. We discuss the utility of 99m-technetium pyrophosphate imaging in cardiac amyloidosis and the role of single photon emission computed tomography. Finally, we review the several forms of cardiac amyloidosis and how they pertain to cardiac scintigraphy.

© 2018 The Authors. Published by Elsevier Inc. on behalf of University of Washington.

This is an open access article under the CC BY-NC-ND license.

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## Case report

A 72-year-old man with a history of chronic systolic heart failure presented with progressive dyspnea and lower extremity swelling. Echocardiogram demonstrated a hyperechoic myocardium, enlarged left atrium, mild right ventricular dilatation with preserved systolic function, and an ejection fraction of 20%-25%. Cardiac amyloidosis was suspected and a serum protein electrophoresis was obtained, which showed

an increase in polyclonal gamma globulins suggestive of a chronic inflammatory reaction; however, no suspicious monoclonal bands were present. Free kappa light chains were 45.61 mg/L (normal < 19.4 mg/L) and the kappa/lambda ratio was 2.01 (normal < 1.65).


The patient underwent cardiac magnetic resonance imaging (MRI), which showed both ventricles to be moderately enlarged and have globally depressed function. The left ventricle demonstrated moderate concentric hypertrophy. Left ventricular ejection fraction was 35% with an absolute cardiac output

\* Corresponding author.

E-mail address: [martinkrupa@gmail.com](mailto:martinkrupa@gmail.com) (M. Krupa).

<https://doi.org/10.1016/j.radcr.2018.06.012>

1930-0433/© 2018 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)



**Fig. 1 – Serial short-axis phase-sensitive inversion-recovery post-contrast magnetic resonance images through the left ventricle demonstrate diffuse, patchy linear and transmural areas of enhancement (arrowheads) predominantly involving the left ventricular myocardium.**

of 5.4 L/min. Delayed enhancement imaging showed abnormal gadolinium kinetics, as well as patchy diffuse enhancement in a pattern typical for amyloid cardiomyopathy (Fig. 1).

The patient subsequently underwent a right heart catheterization with 3 endomyocardial biopsies of the right ventricular septum. Pathology showed myocardial tissue with focal fibrosis; however, no amyloid deposition was present by Congo red stain under polarized light. Immunohistochemistry or mass spectroscopy was not performed.

The discordance between the positive MRI and negative endomyocardial biopsy results prompted further investigation with 99m-technetium pyrophosphate (99mTc-PYP) scintigraphy. Images of the thorax were acquired in planar projections, as well as with single photon emission computed tomography (SPECT), to improve anatomic localization of radiotracer. Cardiac retention of radiotracer was assessed quantitatively by drawing a region of interest over the heart followed by the contralateral right lung and calculating a heart-to-contralateral ratio (H/CL). The patient was injected with 21.0 mCi of 99mTc-PYP and planar images were acquired 1 hour later, which showed significantly increased radiotracer activity in the heart (Fig. 2A) with a calculated H/CL of 1.9 (normal < 1.5; Fig. 2B). SPECT/computed tomography images showed abnormally increased radiotracer activity throughout the myocardium, greatest in the left ventricle (Figs. 3 and 4), consistent with a transthyretin amyloidosis.

## Discussion

Cardiac amyloidosis, often considered as a single clinical entity, is better characterized as a group of diseases caused by the extracellular deposition of fibrillary proteins in the heart [1]. There are three main types defined by different pathological substrates and clinical courses. Cardiac amyloid light-chain (AL) is due to clonal proliferation of immunoglobulin light-chains in the bone marrow leading to protein aggregation and fibrillary deposits. Transthyretin-related cardiac amylo-

dosis is due to misfolding of the transthyretin protein (TTR) with resulting aggregation into fibrillary deposits. It can be due to mutations in TTR, in which case it is called the ATTRm form of cardiac amyloidosis, or due to wild-type, non-mutant TTR, in which case it is called ATTRwt and mainly affects older men [2]. Differentiating between AL and ATTR variants is important because AL portends a worse prognosis and is typically treated with chemotherapy targeting plasma cells. Treatment of ATTR subtypes of cardiac amyloidosis involves liver and/or heart transplantation in select individuals, and conventional heart failure management, with numerous potentially disease-modifying strategies emerging over the past several years [3].

The gold standard for diagnosing cardiac amyloidosis is endomyocardial biopsy. However, non-invasive imaging methods are being increasingly used to allow safer and earlier detection [4]. In a study of 33 patients with endomyocardial biopsy proven cardiac amyloidosis, MRI was shown to have a sensitivity of 94% and specificity of 80% in diagnosing cardiac amyloidosis [5]. Late gadolinium enhancement has also been shown to precede left ventricular morphologic alterations in many cases [6]. However, cardiac MRI is unable to reliably differentiate between AL and ATTR subtypes of cardiac amyloidosis, an important distinction that dictates treatment and prognosis [7].

Over the recent years, there is increasing interest in the use of cardiac scintigraphy for the early detection and differentiation of cardiac amyloidosis [8]. Radiolabeled bisphosphonates were first shown to detect cardiac amyloidosis and distinguish AL from ATTR subtypes with the use of 99m-technetium-3,3-diphosphonate-1,2-propanodicarboxylic acid [9]; however, this isotope is not Food and Drug Administration-approved and not available in the United States. More recently, the widely available isotope 99mTc-PYP has been shown to be able to distinguish cardiac amyloid subtypes. Using the quantitative measure H/CL with a cutoff value >1.5, ATTR subtype amyloidosis can be detected with a 97% sensitivity and 100% specificity [2]. Other quantitative methods have also been proposed, including the “pyrophosphate score,” which is the

Download English Version:

<https://daneshyari.com/en/article/8824935>

Download Persian Version:

<https://daneshyari.com/article/8824935>

[Daneshyari.com](https://daneshyari.com)